PER (PER) News
Follow PER (PER) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Peruvian Metals Corp. (TSXV:PER) Starts Underground Development at Palta Dorada
Peruvian Metals Corp. began underground development at its 100% owned Palta Dorada gold-silver property in Peru to access sulphides, with material to be processed at its Aguila Norte plant.Material DetailsContext by AI A
COMMODITIES | Sep 15, 2026, 12:01 PM UTC
L
Peruvian Metals Corp. Commences Underground Development to Access High-Grade Au-Ag Sulphides at Palta Dorada
Edmonton, Alberta--(. - September 15, 2026) - Peruvian Metals Corp TSXV:PER (OTC Pink: DUVNF) ("Peruvian Metals" or the "Company") is pleased to announce that the Company has commenced underground development at its 100%
COMMODITIES | Sep 15, 2026, 12:01 PM UTC
L
Peruvian Metals reports positive tailings samples and 2026 outlook
Peruvian Metals says it completed a major overall and maintenance program at its Aguila Norte processing plant and reports positive sample results from the tailings area, citing a full production outlook for 2026.
EQUITY | Sep 08, 2026, 01:06 PM UTC
L
Edison issues report on Percheron Therapeutics clinical strategy
TradingView reports Edison issued a report on Percheron Therapeutics, highlighting an investigator-sponsored exploratory study of HMBD-002 in acute myeloid leukaemia (AML).
EQUITY | Sep 04, 2026, 09:06 AM UTC
M
Percheron Therapeutics firm commitments for A$2.3 million placement
Percheron Therapeutics received firm commitments for an institutional placement of A$2.3 million.
EQUITY | Sep 01, 2026, 01:31 AM UTC
M
Percheron Therapeutics to trial Hmbd-002 in acute myeloid leukemia
Percheron Therapeutics says Vanderbilt Health will conduct a clinical trial of Hmbd-002 in acute myeloid leukemia.
EQUITY | Aug 28, 2026, 01:32 AM UTC
H
RTX CORP - RAYTHEON INCREASES AIM-9X MISSILE PRODUCTION CAPACITY TO 2500 PER YEAR
RTX CORP - RAYTHEON INCREASES AIM-9X MISSILE PRODUCTION CAPACITY TO 2500 PER YEAR
GEOPOLITICS | Jun 26, 2026, 12:01 PM UTC